Business Intelligencefor PharmaceuticalCompanies
The recurring failure is not a lack of dashboards. Finance, commercial and the field each report a different number for the same month, so the meeting is spent matching numbers instead of deciding. That is a problem of definitions and sources, and it is fixable.
In short
Hibridge builds commercial analytics and reporting for pharmaceutical companies: sales and market share dashboards, field-force performance, promotional response and channel attribution, territory and target optimisation, and forecasting. Work includes the data engineering underneath, so definitions are consistent and the numbers match across teams.
What we do
Commercial reporting that answers the question that was asked.
Commercial dashboards
Sales, market share, tender performance and portfolio view, with one agreed definition per metric and a visible data source.
Field-force analytics
Coverage, frequency, call quality and territory performance, reported so district managers can act on it, not only defend it.
Promotional response and attribution
Connecting channel activity to prescribing or sales-out movement, with honest confidence ranges instead of implied precision.
Segmentation and targeting analytics
Prescriber potential models and call-plan optimisation, refreshed on a set cycle, not yearly out of habit.
Forecasting
Launch and in-market forecasting with written assumptions and scenario ranges, so a missed forecast can be explained.
Data engineering
Pipelines, a governed metric layer, and quality monitoring. This is what decides whether any of the above is trusted.
Approach
How we build the reporting layer
- 01
Agree definitions
One written definition per metric, signed off across commercial, finance and medical before anything is built.
- 02
Build the layer
Pipelines and a governed semantic layer, so every dashboard draws on the same source.
- 03
Deliver views
Role-specific views. A district manager and a country lead do not need the same screen.
- 04
Sustain
Quality monitoring, a refresh schedule and a named owner, so trust does not decay after month three.
Why it matters
Egypt’s payer mix is shifting as Universal Health Insurance rolls out governorate by governorate while more than half of health spending is still out of pocket. Commercial models built on last year’s payer assumptions go wrong quietly.
57.2%
Paid out of pocket
Egypt spent 4.9% of GDP on health in 2023, about US$141 per capita, with 57.2% of all health spending paid out of pocket by households.
3.13m
As of June 2024, 3.13 million people were enrolled in Egypt's Universal Health Insurance System, covering 81% of the population in the four Phase 1 governorates. The system rolls out in six phases over fifteen years.
World Bank, 2025
Every figure names its publisher. Where a figure is organiser-reported or secondary, we say so.
Frequently asked questions
What data sources do you work with?
Syndicated market data where you are subscribed, internal sales and CRM data, tender and public procurement records, and campaign platform data. We work with what is licensed to you; we do not resell third-party market data.
Can you build on our existing BI platform?
Yes. The platform is rarely the constraint. Most projects are governance and data-model work delivered on your existing tools.
Do you do forecasting for launch products with no historical data?
Yes, using analogue-based methods with the assumptions written down and scenario-ranged. The value is making assumptions clear enough to challenge and revise.
Related services